QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.099044v1 317/1/153    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davies, N. P. Articles by Richardson, D. R. Search for Related Content PubMed PubMed Citation Articles by Davies, N. P. Articles by Richardson, D. R.

CELLULAR AND MOLECULAR

Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates

Children's Cancer Institute Australia for Medical Research, the Iron Metabolism and Chelation Program, Randwick, Sydney, New South Wales, Australia (N.P.D., Y.S.R., D.R.R.); and Division of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin (C.R.C.)

Gallium (Ga) shows significant antitumor activity by markedly interfering with iron (Fe) metabolism, and ⁶⁷Ga is used as a radio-imaging agent for cancer detection. Therefore, the mechanisms involved in ⁶⁷Ga uptake, metabolism, and resistance are critical to understand. The development of tumor lines that are gallium-resistant suggests ⁶⁷Ga uptake may be different in these cells, providing an opportunity for understanding intracellular ⁶⁷Ga and ⁵⁹Fe transport and gallium resistance. In this study, gallium-resistant cells were used to assess ⁶⁷Ga and ⁵⁹Fe uptake using native polyacrylamide gel electrophoresis autoradiography. In contrast to the common view that ⁶⁷Ga and ⁵⁹Fe use the same uptake pathways, we show that the trafficking of these two metal ions is different in cells either resistant (R) or sensitive (S) to gallium. Indeed, in contrast to ⁵⁹Fe, little ⁶⁷Ga is incorporated into ferritin, with most present as a labile ⁶⁷Ga pool. We also report unique changes in ⁶⁷Ga and ⁵⁹Fe trafficking between R and S cells. In particular, in R cells, there was a distinct transferrin-transferrin receptor 1-hemochromatosis protein (HFE) complex (band B) not observed in S cells. Furthermore, because HFE regulates iron and gallium uptake, the two Tf-TfR1-HFE complexes in R cells may be involved in reduced ⁶⁷Ga and ⁵⁹Fe uptake compared with S cells. In S cells, a novel iron-binding intermediate (band D) was identified that was not present in R cells and may be a "sensitivity factor" to gallium. In contrast to the general view that ⁶⁷Ga and ⁵⁹Fe use the same or similar uptake pathways, we show that their distribution and trafficking is markedly different in R and S cells.

Address correspondence to: Prof. Des R. Richardson, Iron Metabolism and Chelation Program, Department of Pathology, Blackburn Building (DO6), University of Sydney, Sydney, NSW 2006, Australia. E-mail: d.richardson{at}pathology.usyd.edu.au

This article has been cited by other articles:

				C. R. Chitambar, D. P. Purpi, J. Woodliff, M. Yang, and J. P. Wereley Development of Gallium Compounds for Treatment of Lymphoma: Gallium Maltolate, a Novel Hydroxypyrone Gallium Compound, Induces Apoptosis and Circumvents Lymphoma Cell Resistance to Gallium Nitrate J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1228 - 1236. [Abstract] [Full Text] [PDF]

				M. Yang, S. H. Kroft, and C. R. Chitambar Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate Mol. Cancer Ther., February 1, 2007; 6(2): 633 - 643. [Abstract] [Full Text] [PDF]

				C. R. Chitambar, J. P. Wereley, and S. Matsuyama Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol. Cancer Ther., November 1, 2006; 5(11): 2834 - 2843. [Abstract] [Full Text] [PDF]